All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was delighted to speak to Wendy Osborne, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.
In this video, Wendy Osborne discusses the Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). She talks about the results from the phase I/II study that assesses the safety and efficacy of this bicistronic approach, which was designed to overcome CD19 escape and CAR T exhaustion.
Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL
Why patients with large B-cell lymphoma fail CAR T-cell therapy & how to manage them
This article explores the potential reasons for relapse following CAR T-cell therapy and the management strategies for this population of large B-cell lymphoma...
ASCO 2016 | Extended Education Session – Immunotherapeutic Approaches to Treating Hematologic Malignancies
Presenters in this Extended Education Session on Immunotherapeutic Approaches included Max Topp, Philippe Armand, Carl June and Veronika...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox